Senior Director
Crescent Biopharma
Senior Director
Crescent Biopharma
Clinical-stage biotech developing solid-tumor therapies
Crescent's operating model requires clear, collaborative accountability between Analytical Sciences and QC. Analytical Sciences leads analytical development and performs the primary technical work through method development, characterization, qualification, validation strategy, and PPQ readiness. QC provides oversight and operational input during early development, assumes increasing responsibility for method transfer, validation execution oversight, laboratory readiness, and GMP testing as programs mature, and takes primary ownership of routine QC operations and analytical method lifecycle management following transition to late-stage and commercial operations.
Success in this role requires a collaborative, hands-on leader who understands both analytical development and commercial QC operations, can establish effective governance across internal and external partners, and thrives in a fast-paced biotechnology environment while balancing scientific rigor, compliance, speed, and pragmatism.
Please note:
Crescent Biopharma is an Equal Opportunity Employer. We are committed to fostering a diverse, inclusive, and equitable workplace where all individuals are valued and respected. Employment decisions are based on qualifications, merit, and business needs, without regard to race, color, religion, gender, sexual orientation, national origin, disability, veteran status, or any other protected status.
Please note, Crescent does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between Crescent and the agency. Crescent will not pay any fees related to unsolicited resumes.
#LI-CBIO
Clinical-stage biotech developing solid-tumor therapies
Crescent Biopharma develops oncology therapies for solid tumors, led by CR-001, a tetravalent bispecific antibody that blocks PD-1 and VEGF to boost anti-tumor immunity while inhibiting tumor blood vessel growth. CR-001 sits in a global Phase 1/2 ASCEND trial, and the pipeline also includes CR-002, an anti-PD-L1 antibody-drug conjugate, and CR-003, an ITGB6-targeted ADC. The company differentiates itself by combining immune checkpoint blockade with VEGF inhibition and other targeted modalities to build an immuno-oncology backbone for solid tumors, supported by strategic partnerships and substantial private placements. Crescent’s goal is to advance multi-agent regimens toward regulatory approval and commercial development for patients with solid tumors.
Explore more opportunities at Crescent Biopharma